# EDGAR Filing Document

**Accession Number:** 0001783036
**File Stem:** 0001213900-25-093251
**Filing Date:** 2025-9
**Character Count:** 2425
**Document Hash:** 9bada60a2691b037e217161ee5068565
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-093251.hdr.sgml**: 20260129

**ACCESSION NUMBER**: 0001213900-25-093251

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250929

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **DATE OF NAME CHANGE:** 20190719

NLS Pharmaceutics Ltd.

The Circle 6

8058 Zurich, Switzerland

September 29, 2025

*<u>VIA EDGAR</u>*

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: NLS Pharmaceutics Ltd. (CIK 0001783036) <br> <u>Registration Statement No. 333-290516 on Form F-1 (the "Registration Statement")</u> 

Ladies and Gentlemen:

NLS Pharmaceutics Ltd. (the "<u>Registrant</u>") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), so that it may become effective on September 30, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| NLS PHARMACEUTICS LTD. | NLS PHARMACEUTICS LTD. |
| By: | /s/ Alexander Zwyer |
|  | Alexander Zwyer |
|  | Chief Executive Officer |

---